Roche, Sepracor files suit against Orchid Chemicals & Pharma.
Roche, Sepracor files suit against Orchid Chemicals & Pharma. Orchid Chemicals & Pharmaceuticals was sued by Sepracor and Roche Holding over plans to sell two new generic drugs in the US, reports Business Standard. Orchid spokesman C H Ram declined to comment on the suits. >Orchid is seeking the US Food and Drug Administration approval to introduce generic versions of the allergy pill Clarinex, for which Sepracor owns patent rights, and Roche`s osteoporosis drug Boniva. Both drugmakers sued last week in the Federal Court in Newark, New Jersey, to block the approvals until patents expire. Sepracor and the University of Massachusetts, which co-owns the patents, claimed in a suit (filed on September 26), that the copy would infringe three patents that expire in 2014 and 2015. Boniva is a tablet taken once a month. Roche contends a generic version will infringe one patent expiring in 2019 and another ending in 2023. The Roche suit against Orchid was filed September 25 in Newark. The cases are Sepracor versus Orchid Chemicals & Pharmaceuticals, and Hoffmann-La Roche versus Orchid Chemicals & Pharmaceuticals, both US District Court, District of New Jersey (Newark).
body{margin:0px; font-family:Arial;} .heading{font-size:22px; padding:3px; color:#002b99; font-family:Tahoma;font-weight:bold} .subhead{background-color:#e3e3e3; font-size:14px; padding:3px;} .newstext{color:#004276; font-size:14px; padding:3px;font-family:arial} .redbar{background-color:#a60000; font-size:10px; color:#FFFFFF;padding:3px;} .black{background-color:#000000; font-size:10px; color:#FFFFFF;padding:3px;} .smalltext{font-size:10px; padding:3px;}
Shares of the company closed down Rs 2.15, or 0.95%, at Rs 223.55. The total volume of shares traded at the BSE was 43,207.(Monday)
By pooja
